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Introduction
Because Huntington’s disease is known to be caused by 
expression of huntingtin (HTT) protein containing an expanded 
polyglutamine repeat region,1 a logical approach to treatment 
of the disease is to administer a therapeutic agent designed 
to lower HTT expression. Ideally, the agent would be admin-
istered systemically and would reduce the expression of only 
the mutant allele in heterozygous individuals by targeting the 
expanded repeat region or a  mutant-allele-associated single-
nucleotide polymorphism.2 However, since chronic reduction 
of the expression of wildtype HTT has been shown to be 
well-tolerated in the rodent and nonhuman primate brain,3–6 
another approach is to directly deliver a nonallele-specific 
siRNA against HTT mRNA to affected brain regions. We have 
previously shown that direct infusion of an siRNA that targets 
both rhesus and human HTT into the putamen of rhesus mon-
keys can achieve significant reduction in HTT mRNA over 
a substantial region of the primate putamen.7 Furthermore, 
we have found that the volume of brain tissue reached by the 
infusion increases in proportion to the rate of fluid flow used 
for the infusion, as long as the rate is not so high as to cause 
loss of fluid due to backflow up the catheter path, or loss into a 
sulcus or ventricle. Risk of these limitations can be minimized 
by appropriate catheter design and careful trajectory planning.
Previous data support that chronic infusion of siRNA into 
a patient’s brain could be accomplished using existing pro-
grammable, implantable and transdermally refillable drug 
pumps positioned in the abdomen, and connected with as yet 
investigational brain infusion catheters implanted into brain 
targets and anchored in place at the skull.7 However, there are 
additional issues beyond fluid backflow concerning the use of a 
relatively high fluid flow rate to maximize brain tissue coverage. 
These include the possibility of eventual fluid  build-up in the 
brain, and the inconvenience of relatively rapid emptying of 
the pump’s reservoir necessitating frequent refilling. A way 
to minimize these concerns without sacrificing the goal of 
maximizing the volume of brain tissue treated by the siRNA 
may be to program the pump to deliver the fluid in a repeated 
pattern, delivering at a relatively high flow rate for a limited 
period of time, then dropping the flow rate to a minimal, basal 
level for an intervening period before repeating the cycle. The 
effectiveness of this type of therapy regimen depends upon 
whether the effect of the siRNA in reducing the expression 
of HTT in the treated brain tissue is durable, lasting for at 
least hours, if not days or weeks, following delivery of the 
fluid to regions of tissue. The effect of siRNA has been found 
to be durable in other organs and tissues of the body. For 
example, the durability of suppression of hepatocyte-derived 
transthyretin protein as measured in serum following a single 
intravenous dose of lipid nanoparticle encapsulated siRNA 
targeting transthyretin (ALN-TTR02) is at least 28–43 days in 
both humans and nonhuman primates.8 However, it has not 
been previously known whether such findings would general-
ize to unencapsulated (“naked”) siRNA delivered to the brain.
The aims of our study were to assess the effect of the dura-
tion of infusion of siRNA on the level of suppression of HTT 
mRNA attained in the putamen and surrounding brain regions, 
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One possible treatment for Huntington’s disease involves direct infusion of a small, interfering RNA (siRNA) designed to reduce 
huntingtin expression into brain tissue from a chronically implanted programmable pump. Here, we studied the suppression 
of huntingtin mRNA achievable with short infusion times, and investigated how long suppression may persist after infusion 
ceases. Rhesus monkeys received 3 days of infusion of Magnevist into the putamen to confirm catheter patency and fluid 
distribution. After a 1-week washout period, monkeys received radiolabeled siRNA targeting huntingtin. After 1 or 3 days of 
siRNA delivery, monkeys were either terminated, or their pumps were shut off and they were terminated 10 or 24 days later. 
Results indicate that the onset of huntingtin mRNA suppression in the rhesus putamen occurs rapidly, achieving a plateau 
throughout the putamen within 4 days. Conversely, loss of huntingtin suppression progresses slowly, persisting an estimated 
27–39 days in the putamen and surrounding white matter. These findings indicate the rapid onset and durability of siRNA-
mediated target gene suppression observed in other organs also occurs in the brain, and support the use of episodic delivery 
of siRNA into the brain for treatment of Huntington’s disease and possibly other neurodegenerative diseases.
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and to evaluate the durability of the suppression in the tissue 
after delivery is stopped. We implanted drug delivery pumps 
and intracranial catheters into rhesus putamen and delivered 
a dilute solution of the magnetic resonance imaging (MRI) con-
trast agent gadopentetate dimeglumine (Magnevist) for a period 
of several days, during which time MR imaging was used to 
confirm catheter patency and document intraparenchymal fluid 
distribution. After a 1-week washout period, we delivered radio-
labeled siRNA via the same systems for various periods of time, 
and terminated animals at various time points. The distribution 
of the siRNA in the brain was assessed via autoradiography 
and the suppression of HTT mRNA by the siRNA at various 
locations in the brain was assessed via RT-qPCR. Our data 
support that, as has been found in other organs and tissues, the 
effect of siRNA on the level of expression of the targeted gene 
is durable for several weeks in the brain. Furthermore, the onset 
of the siRNA effect is rapid, such that a cyclical delivery regi-
men involving an intermittently high flow rate might be used to 
maintain a fairly continuous therapeutic effect in targeted brain 
regions extending well beyond the volume reached by a lower 
flow rate of delivery. These findings may be applicable not only 
to Huntington’s disease treatment, but also treatment of other 
neurodegenerative diseases for which the lowering of a toxic 
gene product in the brain may be efficacious.
Results
Fifteen adult female rhesus monkeys were implanted with 
intracranial catheters primed with 5 mmol/l Magnevist in 
phosphate-buffered saline (PBS) and connected to abdomi-
nally implanted infusion pumps. All animals were infused 
with Magnevist from their implanted pump at a rate of 0.3 μl 
per minute for 3 days. In all animals, the catheter needle tips 
were found to be within a 2 mm radius of the target location in 
the putamen based on the postoperative MRI taken immedi-
ately after catheter placement (on day −10). Also, all catheters 
were patent based on Magnevist visualization in the brain via 
the MRI taken 3 days postsurgery (on day −7). After an inter-
vening 7-day infusion of PBS at a rate of 0.1 μl per minute (for 
“washout” of the Magnevist), the pump reservoir was filled (on 
day 0) with radiolabeled anti-HTT siRNA for all animals but a 
PBS control group (n = 3), and the infusion continued at a rate 
of 0.3 μl per minute for 2 or 4 days. The purpose of these time 
periods was to yield 1- and 3-day infusions of the siRNA into 
the brain, given that the time required for the siRNA to reach 
the brain from the abdominal pump, at a rate of 0.3 μl/minute, is 
about 24 hours. At the end of this infusion, either the monkeys 
were terminated, or the infusion was stopped for a period of 10 
or 24 days at which point the animals were terminated (Fig-
ure 1a). All 15 catheters were determined to be patent at the 
time of the animal’s necropsy based on a postmortem check of 
fluid delivery through the catheter from the pump.
Distribution of infusates
To determine whether an infusion of Magnevist would have 
utility in assessing the extent of siRNA distribution achieved in 
an individual’s brain, the volume of distribution of Magnevist 
was determined from the T1-weighted MRI images taken at 
the completion of the 3 days infusion period and compared 
to the distribution of siRNA assessed later by autoradiogra-
phy (Figure 1b,c). The volume of Magnevist distribution was 
obtained by thresholding the gray scale MRI image using 
a voxel value that was 10% of the maximum T1 intensity 
obtained from the Magnevist signal at the catheter tip in the 
putamen. Since the absolute concentration of Magnevist did 
not vary at this point, it provided a reference to standardize 
the threshold from scan to scan. The volume of siRNA deliv-
ery was quantified by identifying the regions of autoradiogra-
phy sections with a signal corresponding to 0.65 mg or more 
of siRNA per gram of tissue, which is the concentration of 
siRNA previously found to correspond to approximately 45% 
suppression of HTT mRNA.7
 We refer to this as the “volume of 
≥45% suppression.” Only the animals terminated immediately 
after 2 days of infusion (group 2, 1 day of siRNA delivery to the 
brain) or 4 days of infusion (group 3, 3 days of siRNA delivery 
to the brain) had sufficient radioactive material in the brain 
tissue to visualize intraparenchymal distribution of siRNA by 
autoradiography. All other groups (with longer survival inter-
vals postinfusion) had negligible signal. The volume of ≥45% 
suppression (mean ± SE) obtained in the monkeys at time 
points 1 and 3 was 584.8 ± 45.6 and 674.5 ± 58.4 mm3, respec-
tively, a difference that is not statistically significant (t = 1.21, 
df = 4, P = 0.29). The volume of Magnevist distribution in these 
groups was 1,262.8 ± 307.9 and 1,747.8 ± 641.8 mm3, respec-
tively (t = 0.68, df = 4, P = 0.533). For every animal, the vol-
ume of Magnevist distribution exceeded the volume of ≥45% 
suppression, but the difference between the volume of Magn-
evist distribution and the volume of ≥45% suppression was 
highly variable from animal to animal (Figure 2) and was not 
significant (875.7 ± 350.6, t = 2.5, df = 5, P = 0.055). The cor-
relation between the volumes was r = −0.32 (P = 0.54). Thus, 
a quantitative relationship between the volume of Magnevist 
distribution and the subsequent siRNA volume of ≥45% sup-
pression could not be defined using the observations from 
this small number of animals.
Onset of suppression
Using HTT suppression measurements normalized to 
the corresponding PBS group averages (on a punch 
 location-by-punch-location basis), a mixed-model analysis of 
variance (ANOVA) of HTT suppression with punch location as 
the within-monkey factor and membership in groups receiv-
ing siRNA for zero (PBS group), 1, or 3 days as the between 
monkey factor was performed. Two outlier observations (with 
standardized residuals more than 5.0 standard deviations from 
their respective group mean) were omitted from the analysis: 
one punch from one monkey in the PBS group (calculated 
percent suppression = −96.13%, i.e., an apparent increase 
in HTT expression) and one punch from one monkey in the 
siRNA1+3 group (calculated percent suppression = −52.20%, 
also indicating an apparent increase in HTT expression). The 
ANOVA resulted in a significant difference among punch loca-
tions (F = 2.12, df = 68, 359, P < 0.001) and a significant inter-
action effect of punches by treatment group (F = 1.35, df = 136, 
359, P = 0.015), indicating there is evidence for true differences 
in the level of HTT mRNA suppression at various anatomical 
sites depending upon the treatment administered, as expected. 
To further characterize the relationship between level of HTT 
mRNA suppression, location in the brain, and treatment group, 
www.moleculartherapy.org/mtna
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the punches were categorized according to whether they 
were within or outside the putamen (the site of the infusion), 
and a mixed-model ANOVA was performed with membership 
in groups receiving siRNA for zero (PBS group), 1, or 3 days 
as the between-monkey factor, and punch category (within or 
outside the putamen) as a within-monkey factor, with punches 
nested within punch category. The ANOVA resulted in a signifi-
cant interaction between punch category and treatment group 
(F = 14.99, df = 2, 493, P < 0.001). This interaction is portrayed 
in the graph in Figure 3, which shows no differences among the 
monkeys receiving PBS or siRNA in HTT mRNA suppression 
in locations outside the putamen, but a difference among the 
monkeys receiving PBS or siRNA for differing lengths of time in 
HTT mRNA suppression in locations within the putamen.
Separately analyzing the punches taken from other ana-
tomical regions in the brain (caudate, cerebral cortex, and 
white matter structures surrounding the basal ganglia) did 
not show any significant differences in HTT mRNA suppres-
sion across treatment groups nor any treatment group by 
punch location interaction in regions beyond the putamen 
(data not shown).
To more fully characterize and mathematically model the 
onset of suppression resulting from siRNA infusion into the 
rhesus putamen, a meta-analysis was performed using the 
data from groups 2 and 3 from the current study (siRNA1+1 
and siRNA 1+3, respectively) and HTT suppression data 
from the same tissue punch locations from five additional 
monkeys used in a prior study.7 These five monkeys received 
the same siRNA at the same concentration and infusion rate, 
and via the same infusion system implanted by the same sur-
gical team as the current study, for 7 days prior to termination. 
As with the monkeys in the present study, it took 24 hours for 
the siRNA to reach the brain from the pump reservoir in the 
abdomen, so the data from this latter group of five monkeys 
Figure 1  Study design and distribution of infusates. (a) Diagram of the experimental groups and time course of events in the study. 
Diamonds indicate MRIs taken after implantation of the delivery hardware and at later points in the study. Groups 4 and 5 had their pumps 
completely turned off after 4 days of infusion. (b) Distribution of Magnevist after 3 days of delivery to the putamen at a rate of 0.3 μl per minute. 
(c) siRNA distribution in the same monkey after 3 days of delivery to the putamen at a rate of 0.3 μl per minute, visualized by autoradiography. 
The autoradiography is color-coded for siRNA concentrations. Magenta represents a potentially “efficacious” level of siRNA (≥ 0.65 mg of 
siRNA per gram of tissue). At this coronal plane, there was near complete coverage of the putamen with some spread to adjacent structures, 
in particular some tracking of infusate dorsally into cortex. Scale bars = 1 cm.
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(“Group 6”) serves as an additional time point at day 6 in the 
modeling of suppression onset. The assay of the level of sup-
pression of HTT mRNA in the tissue punches from the Group 
6 monkeys was conducted using the same cDNA standard 
to define the level of HTT mRNA in rhesus putamen consid-
ered “zero percent suppression” as was used in the current 
study (see Materials and Methods.) Therefore, the percent 
suppression information is on the same measurement scale 
across studies, such that a meta-analysis is meaningful.
In this meta-analysis, using just the tissue punches from 
the locations inside the putamen, a mixed-model ANOVA of 
HTT suppression (normalized to corresponding PBS group 
averages) with punch location as a within-monkey factor and 
membership in groups as the between-monkey factor was 
performed. The groups included were Groups 1, 2, and 3 from 
the current study (c.f. Figure 1a), and Group 6 from the prior 
study, with the latter three groups receiving siRNA infusion 
into the putamen for 1, 3, or 6 days, respectively. The ANOVA 
resulted in significant differences among groups (F = 30.91, 
df = 3, 10, P < 0.001), and among the various punches 
(F = 2.41, df = 39, 334, P < 0.001). One-sample T-tests of the 
average suppression across all putamenal punches in Group 
2, Group 3, and Group 6 (against the null hypothesis of zero 
suppression) showed that suppression (relative to PBS) 
was significantly greater than zero after after 3 days (mean 
difference = 13.47%, SD = 7.85%, T = 2.97, df = 2, P < 0.05, 
one-tailed) and significantly greater than zero after 6 days of 
siRNA exposure (mean = 38.64%, SD = 4.41%, T = 19.75, 
df = 4, P < 0.001).
Continuing with the meta-analysis, an ANOVA of the 
overall average HTT suppression in each monkey’s puta-
men derived from just those punches in the putamen that 
were 4 mm away from the infusion site (the “B” series of 26 
punches, see Supplementary Materials) showed a signifi-
cant difference among groups (F = 36.08, df = 3, P = 0.001). 
Suppression averaged 4.1% above the corresponding PBS 
group values after 1 day and 18.4% after 3 days. This gain 
of 14.3 percentage points in average HTT suppression in 
Group 3 (siRNA1+3) compared to Group 2 (siRNA1+1) is 
statistically significant (P < 0.05 by the Tukey post-hoc test of 
pairwise comparisons). These data indicate that continuing 
to expose the putamen to siRNA for additional days after one 
day of siRNA exposure is effectual and perhaps necessary 
for therapeutic benefit.
A main objective of the current study was to character-
ize whether the onset of suppression is linear or curvilin-
ear, the shape of any curvilinear relationship, and the likely 
timing of the asymptote of suppression levels, and thus the 
time point beyond which continuous exposure of the brain 
tissue to the siRNA could be suspended for awhile without 
sacrificing the potential for even greater suppression. For 
this purpose, the analysis plan was to identify the best-fitting 
linear regression line and the best fitting-fitting parameter 
values for two curvilinear functions, each computed on a 
 punch-location-by-punch-location basis, in a meta-analysis 
using Groups 2, 3, and 6, mathematically fixing the percent 
suppression at time zero to zero. Figure 4 illustrates the shape 
of the equations. Using the difference in percent suppression 
above the PBS group average at the corresponding punch 
location in the brain as the measure, this analysis yielded 
no consistent result, and no consensual estimate regarding 
the time of siRNA exposure sufficient to reach an asymptote. 
Rather, in 11 of 40 punch locations, the  best-fitting relation-
ship between time and suppression was concave down, in 4 
punch locations (not anatomically contiguous) the  best-fitting 
Figure 2 Volumes of Magnevist and siRNA distributions 
by monkey. Data plotted are the volume of siRNA at a 
concentration ≥ 0.65 mg of siRNA per gram of tissue and the volume 
of Magnevist distribution. Lines connect values from the same 
monkey (gray dotted lines, monkeys receiving siRNA in putamen 
for 1 day; solid black lines, monkeys receiving siRNA in putamen 
for 3 days).
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relationship was sigmoidal, in 11 locations it was linear, and 
in 14 locations it followed an exponential growth curve, imply-
ing no limit to the amount of suppression attainable (or at 
least that in a variety of non-contiguous punch locations 
scattered through the putamen the asymptote was not yet 
attained after 6 days of exposure).
Because of the possibility that these complex and uninfor-
mative results were due to the analysis of the difference in 
suppression above the corresponding PBS averages, possibly 
exacerbating variability in the data, the analysis was performed 
directly on the percent suppression over the zero point provided 
by the common cDNA standard (see Methods). This analysis 
yielded consistent, consensus results across punch locations. 
In 37 of 41 punch locations, the equation type that best fits 
the data is curvilinear, concave down (see  Supplementary 
Table S1), indicating there is minimal lag in the initiation of the 
suppression (else, a sigmoidal curve would fit better) and an 
asymptote to the maximum suppression that can be attained 
occurs within a 6-day period. On average, the curve fits across 
the 41 punch locations in the putamen indicate that 97% of 
the maximum attainable suppression of HTT is reached within 
3.23 ± 0.25 days (mean ± SE) of infusion initiation. There is 
no significant relationship between the distance of the punch 
from the infusion site and the predicted number of days to 
reach 97% of the maximum attainable suppression at that site 
 (correlation = −0.28, P = 0.116, n = 33).
A visualization of how the level of suppression of HTT 
mRNA in the various punch locations in putamen of the 
monkeys varied with differing days of delivery of the siRNA 
is provided in Figure 5. Supplementary Materials present 
the data (means ± SE) in tabular form in  Supplementary 
Table S2, with larger schematic images showing the 
locations of the tissue punches in the monkey brain provided 
in  Supplementary Figure S1.
Duration of suppression
Another main objective of the current study was to deter-
mine how long delivery of siRNA to putamenal tissue could 
be suspended before suppression of HTT would be substan-
tially lost. To investigate the duration of suppression of HTT 
by the siRNA, we again used HTT suppression measure-
ments normalized to the corresponding PBS group (Group 1) 
averages on a punch location-by-punch-location basis, and 
performed a mixed-model ANOVA of HTT suppression with 
punch location as the within-monkey factor and membership 
in the group terminated at 0, 10, or 24 days following cessa-
tion of the siRNA delivery as the between-monkey factor. This 
ANOVA resulted in a significant difference among groups 
(F = 12.03, df = 2, 6, P = 0.008), among punch locations 
(F = 2.75, df = 69, 355, P < 0.001) and interaction between 
punches and group (F = 1.33, df = 138, 355, P = 0.018).
Restricting the analysis to punches located within the puta-
men produced the following ANOVA results: there are signifi-
cant differences among the experimental groups (F = 10.67, 
df = 2, 6, P = 0.010) and among the various punches 
(F = 2.29, df = 40, 203, P < 0.001). Furthermore, there is no 
evidence that the differences among experimental group var-
ied by punch location (interaction of group × punch, F = 0.79, 
df = 80, 203, P = 0.891). That is, the time course of the sup-
pression was similar regardless of the particular location of 
the punch within the putamen. Planned follow-up questions 
regarding the durability of suppression were addressed by 
T-tests at the various time points, separately, as shown in 
Figure 6a. Figure 6a also shows that when the percent sup-
pression is normalized by subtracting the averages of the 
PBS group (Group 1), none of the other groups’ averages are 
significantly different from zero, and the average of Group 
5 (24 days after cessation of siRNA delivery) trends below 
zero (P = 0.079, two-tailed) which would be indicative of a 
“rebound” effect with even greater HTT expression (above 
baseline) after the siRNA treatment is stopped. However, 
there is no evidence of such a rebound effect in the HTT 
suppression values using zero point defined by the common 
cDNA standard; the apparent increase in HTT expression is 
an artifact of the mathematical subtraction of the PBS group 
values.
To determine whether the decline in suppression with time 
is linear or curvilinear, the best-fitting linear regression line 
and the best-fitting parameter values for two curvilinear func-
tions (concave up and concave down) were computed on a 
punch-location-by-punch-location basis. Figure 6b illustrates 
the shape of these three equations. Using the difference in 
percent suppression above the PBS group average at the cor-
responding punch location in the brain as the measure, this 
analysis yielded inconsistent and uninformative results. In 19 
of 38 punch locations, the best-fitting relationship between time 
and suppression was linear, in 16 of 38 punch locations the 
best-fitting relationship was concave down, in 1 the  best-fitting 
relationship was concave up, and in 2, the  best-fitting rela-
tionship was none of these, but rather a paradoxical quadratic 
Figure 4 Illustration of alternative curve fits for time course of 
suppression onset. Linear, sigmoidal, and concave down curve fit 
to onset of suppression of huntingtin measured in RNA from punch 
location B02 from the putamen of monkeys after 1, 3, and 6 days of 
siRNA delivery (group 2, group 3, and group 6, respectively). Dotted 
line: best linear fit, Supp = 12.84 + (8.53 * day); gray dashed curve: 
best sigmoidal fit, Supp = 57.69 * exp(–exp(1.45 – 1.83 * day)); solid 
black curve = best concave down fit, Supp = 59.88 * (1 – exp(–
0.73*day)). The curve fits for each punch location in the putamen 
are provided in the supplemental materials. †Group 6 is the group 
from a prior study used for this meta-analysis of suppression onset.
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(inverted U) relationship, with greater suppression in the group 
assayed 10 days after siRNA delivery cessation than in the 
groups assayed at 0 or 24 days after siRNA delivery cessa-
tion. Estimates across punch locations of the number of days 
from the cessation of siRNA administration to the point in time 
when the level of suppression would be back to zero could not 
be calculated using either the linear or concave down model 
(leading to a nonsensical −43.3 days in the linear case, and a 
negative logarithm in the concave down case).
Therefore, as with the onset characterization, the analy-
sis to characterize duration of suppression was performed 
directly on the percent suppression over the zero point pro-
vided by the common cDNA standard. This analysis yielded 
consistent results. Regression analyses yielded a statistically 
significant coefficient for the linear term in the majority of 
punches (24 of the 38). A concave up (exponential decay) 
model is the best fit to the data in only 8 out of 38 punch 
locations (see Supplementary Table S3) and only 3 punch 
Figure 5 Suppression onset in the putamen. The average suppression of HTT mRNA measured in punches taken from the putamen in 
the coronal slab containing the infusion site and the 2-mm slabs anterior and posterior to that slab is shown for each of three time points.
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locations yielded a statistically significant coefficient for any 
curvilinear term (concave up or down). Thus, the most par-
simonious model for the decay of HTT mRNA suppression 
based on these data is a linear function of time, declining at 
the rate of about 1.4 percentage points per day. The average 
estimate (across punches) for the number of days from the 
cessation of siRNA administration to the point in time when 
the level of suppression would be back to zero using this lin-
ear model is 39.3 days (95% confidence interval = 31.4–47.1 
days). A more conservative estimate using a concave down 
model is 27.3 days (95% confidence interval = 25.4–29.1 
days).
A visualization of how the level of suppression of HTT 
mRNA in the various punch locations in putamen of the mon-
keys varied with time since the cessation of the siRNA deliv-
ery is provided in Figure 7. The same data (means ± SE) are 
presented in tabular form in Supplementary Table S4.
Discussion
We believe the data presented here are the first of their 
kind for siRNA administered to the nonhuman primate brain. 
Specifically, the data provide information about the time 
course of the onset and durability of siRNA-mediated sup-
pression of a target gene such as HTT in the putamen. The 
results suggest that siRNA might be effectively delivered to a 
human patient’s putamen via an episodic dosing paradigm as 
an alternative to continuous infusion.
Comparison of Magnevist and the siRNA infusion in this 
study showed that whether the siRNA had been delivered 
for 1 or 3 days, the Magnevist distribution was greater than 
the siRNA distribution (volume of siRNA tissue concentra-
tion previously found7 to be equivalent to ≥45% suppression) 
that was later attained in the same animal. The Magnevist 
and siRNA distributions bore enough similarity that it may be 
reasonable to use Magnevist in the clinical setting as a sur-
rogate for siRNA in terms of visualizing the directions of the 
anatomical spread of the siRNA, in addition to confirmation 
of catheter patency, system integrity, and fluid delivery into 
tissue. It is also possible that an MRI of Magnevist distribu-
tion taken sooner after infusion initiation would not yield as 
large and variable an overestimate of the siRNA distribution 
as was found here. However, pending further research, this 
could not be used clinically for an estimate of the extent of 
siRNA spread and the resulting extent of HTT suppression 
in a patient.
The three monkeys receiving PBS (Group 1, 3 days of 
Magnevist, followed by 7 days of PBS delivered at 0.1 ul/min-
ute for Magnevist washout, followed by PBS at 0.3 μl/minute 
for 4 days) showed an unexpectedly low level of HTT mRNA 
normalized for glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) mRNA expression and compared to the zero point 
provided by the common cDNA standard (see Methods). This 
resulted in apparent HTT suppression by PBS alone. The 
reason for this result is unclear, and it is inconsistent with 
several previous studies of PBS versus ALN-HTT01 delivery 
to the rhesus putamen by this delivery system, including the 
results from five monkeys receiving PBS only in a prior study,7 
for which the average HTT mRNA suppression in the puta-
men, measured by the same technique and against the same 
standard used here, was 2.98 ± 4.47% (mean ± SD, n = 5). In 
any case, a significantly greater level of HTT suppression in 
the putamen was seen in the monkeys receiving the siRNA 
for 3 days, compared to this contemporaneous PBS group. 
However, for purposes of the meta-analysis to characterize 
the relationship between time and onset of HTT suppression, 
Figure 6 Suppression durability in the putamen. (a) Mean and standard error of suppression averaged over all tissue punches from 
the putamen in monkeys terminated 0, 10 or 24 days after siRNA delivery cessation (groups 3, 4, and 5, respectively). Gray-filled bars 
are the suppression values based on the zero point provided by the common cDNA standard; white bars are the suppression values after 
subtracting the corresponding phosphate-buffered saline Group1 average from the same tisue punch locations. **P < 0.01 versus zero, 
*P < 0.05 (Tukey post-hoc test), †P < 0.10 versus zero, two-tailed; ns = not significant. (b) Linear, concave up, and concave down curve fit to 
the decline of suppression measured in RNA from punch location B14 from the putamen of monkeys at 0, 10, and 24 days after cessation 
of siRNA delivery using the suppression values based on the zero point provided by the common cDNA standard. Dotted line: best linear 
fit, Supp = 56.34 + (–1.21 * day); gray-dashed curve: best concave up fit, Supp = 56.13 * exp(–0.027 * day); solid black curve: best concave 
down fit, Supp = 54.10 – (exp(0.14 * day)). The curve fits for each punch location in the putamen are provided in the supplemental materials.
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the unexpected low level of HTT in Group 1 made it impos-
sible to identify a consistent relationship between time and 
HTT suppression if the data were analyzed as the difference 
in suppression over the PBS group. In contrast, direct analy-
sis of the level of suppression against the zero point provided 
by the common cDNA standard yielded a consistent relation-
ship and plausible estimate of the time to maximal suppres-
sion. In this meta-analysis of the data on a punch-by-punch 
basis (41 repetitions of the same analysis), 88% of the punch 
locations yielded a best-fitting mathematical equation of the 
concave down form, modeling the increase in suppression 
over time as reaching 97% of its asymptote within 3–4 days 
(3.22 ± 0.25 days, means ± SE; Supplementary Table S1). 
A risk of this analysis is that the suppression assessed may 
be a mixture of true siRNA effects (i.e., RNA interference) 
plus other effects such as the effect of fluid infusion into the 
Figure 7 Suppression durability in the putamen. The average suppression of huntingtin mRNA measured in punches taken from the 
putamen in the coronal slab containing the infusion site, and the 2-mm slabs anterior and posterior to that slab is shown for each of three 
time points.
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putamen. However, to the extent that these other effects on 
HTT expression are reproducible, they may be part of the 
overall effect of the therapy in its clinical application.
Based on the meta-analysis, the median value of the 
asymptotic level of suppression calculated across all tis-
sue punches in the putamen was 48.4% (Supplementary 
Table S1). In animal models of Huntington’s disease, reduc-
tion of mutant HTT expression by ~45% to ~75% has been 
sufficient to produce phenotypic improvement in behavior 
as well as neuropathology.3,4,9–12 For example, Harper et al.9 
found that reduction of the mutant HTT transcript in HD-
N171-82Q mice by 51–55% led to significant improvements 
in gait deficits and rotarod performance. Kordasiewicz et al.10 
report that an antisense oligonucleotide that reduced the pro-
duction of human mutant exon1 mRNA in the R6/2 mouse 
brain by 43 ± 5% was sufficient to block further brain weight 
loss and significantly extend the lifespan of these mice. In 
the primate study reported by Kordasiewicz et al.,10 4 mg of 
antisense oligonucleotide was delivered to the cerebrospinal 
fluid of rhesus monkeys per day for 21 days, with the result 
that HTT mRNA was suppressed by 53% (i.e., to 47% of 
control levels) in the frontal cortex and by about 25% in the 
caudate nucleus, though the latter level was not statistically 
significant. Of course, whether this amount of suppression 
in treated tissue will be sufficient to achieve a therapeutic 
effect in patients affected by the human disease will only be 
determined by clinical trials. It appears likely that approaches 
to HTT-lowering might advance to first-in-human trials on the 
assumption that about 25–55% suppression of HTT mRNA 
and protein in the brain will be sufficient to have a therapeutic 
effect on brain tissue, with the hope that sufficient key regions 
of tissue can be treated to produce a beneficial outcome for 
the patient.
It is notable that 3 days versus 1 day of siRNA delivery to 
the brain resulted in a greater level of suppression of HTT in 
the treated tissue, but not in a greater volume of the putamen 
treated (see left endpoints of lines in Figure 2). This suggests 
that the volume of tissue treated may be a function of the rate 
of delivery of fluid to the brain from the infusion system rather 
than the number of days of delivery per se. Clinically, this 
could be controlled by how the pump is programmed.
A limitation of this study is that the time course of HTT sup-
pression was measured across animals, rather than within 
the same animals over time. It is assumed but cannot be 
guaranteed that this time course reflects what will occur in 
an individual’s brain over time. In addition, the level of sup-
pression was measured in tissue punches, and not individual 
cells; it is likely that the level of suppression attained in indi-
vidual cells or cell types is variable. Further research would 
be needed to characterize siRNA uptake and HTT suppres-
sion in various cell types, and the amount of mutant HTT sup-
pression that is adequate for rescue of function in various 
cell types. Nevertheless, based on the tissue punches taken 
from the putamen of the animals, not only from the slab con-
taining the infusion site, but also from multiple slabs anterior 
and posterior to the infusion, the study showed that the onset 
of HTT mRNA suppression resulting from the infused siRNA 
was fairly rapid.
Monkeys terminated at 10 or 24 days after cessation of 
siRNA delivery had insufficient autoradiography signals to 
allow for distribution analysis, suggesting that after delivery 
of siRNA is stopped, washout of siRNA to well below 0.65 mg 
per gram of tissue occurs in less than 10 days. However, 
significant suppression of HTT in the treated region of the 
brain persists at this time point. Based on tissue punches 
from throughout the putamen, the decline in the percent sup-
pression of HTT upon cessation of delivery of the siRNA is 
slow, and most parsimoniously described as a linear function 
of time, taking about 33 days for the suppression to return 
to zero. An alternative, concave down curvilinear model for 
the decline in percent suppression of HTT also fits the data 
obtained in this study, but with less statistical confidence. 
This model predicts it would take about 25.9–26.8 days 
for suppression to return to zero upon cessation of siRNA 
delivery. Because it is much more common for biological 
processes to be nonlinear rather than linear in nature, it 
is tempting to assume that the nonlinear model is correct. 
A mechanistic explanation for what is happening at the molec-
ular level may be that the siRNA molecules, once inside the 
cell (and associated with the RISC complex) undergo a time-
dependent wearing out, such that the probability that any 
given molecule of siRNA will cease to suppress HTT mRNA 
is a steadily increasing function of how long that particular 
molecule of siRNA has been inside the cell. Such a time-
dependent  loss-of-function can yield a curvilinear decline in 
suppression overall for the population of molecules in a cell 
 (Supplementary Figure S2). Given the limited number of 
time points in this study, we cannot distinguish between a lin-
ear and  concave-down model for the decline. Pending further 
studies providing more time points, the most parsimonious 
course of action is to assume the linear model is the best 
description of the time course of the decline in siRNA-medi-
ated suppression of HTT mRNA in the brain. It is notable, 
however, that the results of this study rule-out a concave-up, 
exponential decay model for the decline in suppression of 
HTT by the siRNA. Mechanistically, this means we can rule-
out that the decline in suppression by the siRNA is governed 
by the physical washout of the siRNA from the brain.
This study supports the conclusion that 3–4 days of siRNA 
infusion into the brain is sufficient time to achieve the maxi-
mum suppression of HTT mRNA attainable by this siRNA. 
Computational modeling studies are underway to estimate 
the flow rate for the infusion that may yield optimal coverage 
of the HD patient’s brain tissue; ideally, the maximum flow 
rate used in human patients can be higher than that used in 
the rhesus monkey. After 4 days, the flow rate would auto-
matically be reduced to the minimum programmable rate of 
the infusion pump, and continue at this rate for 10–24 days. 
Then the process would repeat, resulting in a recurring cycle 
of 14 or 28 days in length. This episodic delivery pattern 
incorporating a high flow period may produce a therapeutic 
effect over a broader volume of brain tissue than produced by 
a constant infusion at a lower rate, while offering the advan-
tages of slower depletion of siRNA from the drug pump reser-
voir, and avoidance of any potential problems that might arise 
from continuously delivering exogenous fluid into the brain at 
a relatively high rate.
In the report cited earlier, Kordasiewicz et al.10
 found evi-
dence in mouse models of Huntington’s disease that the 
beneficial effects of HTT-lowering on the animal’s phenotype 
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out-lasted not only the delivery of the oligonucleotide and 
its presence in the brain, but even the time period for which 
HTT protein expression was reduced. This finding has led to 
the hypothesis that a “holiday” from the mutant HTT protein’s 
effects on a neuron may be sufficient for a neuron to recover 
some of what has been, so far, its life-long ability to cope 
with mutant HTT’s toxic effects.13 If so, periodic delivery of 
a  HTT-lowering agent may have beneficial effects that are 
more stable than might otherwise be predicted from the direct 
effects on the agent on gene expression, such that the exact 
amount of time between doses may not be highly critical, at 
least in the case of Huntington’s disease.
To the extent that both the distribution and uptake of the 
siRNA used in this study are representative of the distribu-
tion and uptake into brain tissue of siRNA that might be used 
against other disease targets, these results suggest that epi-
sodic delivery of siRNA may be useful in a many future thera-
pies for neurological disorders.
Materials and methods
Brain infusions. Fifteen adult female rhesus (Macaca mulatta) 
monkeys were obtained from a commercial supplier (Covance, 
Alice, TX) and equally divided into five test groups. All animals 
were implanted with the intraparenchymal brain infusion hard-
ware consisting of a Medtronic SynchroMed II infusion pump 
(model 8637-20, Medtronic, Minneapolis, MN), and inves-
tigational catheter system consisting of a sutureless pump 
 catheter, cranial anchor and cranial catheter (Medtronic). 
All animal procedures were approved by the University of 
Kentucky Institutional Animal Care and Use Committee 
and conducted in facilities accredited by the Association for 
Assessment and Accreditation of Laboratory Animal Care.
Surgical methods. For each animal, a series of presurgical 
T1-weighted and T2-weighted MR images was obtained prior 
to the surgery for screening and surgical planning. The pre-
operative MRI was read to confirm that there were no brain 
abnormalities, and to plan the stereotactic coordinates for 
the catheter implantation. On the day of surgery, an MRI was 
obtained postoperatively to verify that the infusion point (catheter 
needle tip) was within a 2 mm radius of the intended surgical 
target: the approximate center of the putamen at the rostro-
caudal and lateral coordinates and 3 mm above the ventral 
border of the putamen at the vertical coordinate. A second 
postoperative MRI was conducted after 3 days of infusion of 
Magnevist (5 mmol/l, Bayer HealthCare Pharmaceuticals, 
Wayne, NJ) at a rate of 0.3 μl/minute to confirm catheter 
patency and to determine infusate distribution. All groups had 
a final MRI taken on the day of termination.
Briefly, the implant procedure was as follows. After induction 
of anesthesia, the animal was positioned in an  MRI-compatible 
stereotaxic apparatus and the surgical sites prepped using 
aseptic techniques. Then, a burr hole was drilled through the 
skull under sterile field conditions at a location derived from 
the preoperative MRI used to plan the catheter trajectory. 
Using a micro manipulator, a cannula containing an obtura-
tor was lowered into the brain at a rate of 1 mm per minute 
to a depth of 7 mm above the target. Next, the obturator was 
removed from the cannula and a needle-tipped intraparen-
chymal infusion catheter (investigational device, Medtronic) 
containing a hollow stylet was lowered until its needle tip was 
at a depth corresponding to the planned target. Throughout 
this procedure, sterile saline was infused through the hollow 
stylet and catheter at a rate of 1 μl/minute to maintain cath-
eter patency. The catheter was secured at the skull using a 
cranial anchor (investigational device, Medtronic) designed 
to prevent mechanical forces from the extra-cranial catheter 
tubing that connects to the abdominally implanted pump from 
being transmitted to the intracranial portion of the catheter. 
An infusion pump (SynchroMed II Model 8637-20, Medtronic) 
was filled with 5 mmol/l Magnevist, then implanted into a 
subcutaneous pocket in the animal’s abdomen. A catheter 
 tunneled subcutaneously from the pump’s outlet port to the 
site of the cranial anchor was also filled with 5 mmol/l Magn-
evist and connected to the inlet port of the cranial anchor. 
The pump was programmed to deliver a single 100 μl bolus 
of fluid at a rate of 10 μl/minute for 10 minutes to ensure cath-
eter patency, then the flow rate was reduced to a basal rate 
of 0.3 μl/minute for 3 days of Magnevist delivery. The animal 
was taken from surgery to MRI immediately postoperatively 
to confirm correct catheter placement and patency.
siRNA development. An siRNA molecule (Alnylam Phar-
maceuticals, Cambridge, MA) that targets a region of HTT 
mRNA that is 100% homologous between rhesus and human 
was developed by first identifying potential target sequences 
and screening them by Alnylam-proprietary criteria for likely 
activity and specificity. Forty-two siRNA candidates were 
then screened in vitro in HeLa cells for activity against human 
HTT. Top candidates were further assessed for potency in 
Neuroscreen-1 and U87MG cell lines, and empirically tested 
in Cos7 cells to rule out inhibition of 17 possible off-target 
genes identified based on partial sequence match to the 
siRNA sequence. The lead candidate (ALN-HTT01, see 
Stiles et al.7
 for sequence) inhibits HTT in vitro with an IC50 
of 56 pM, but does not attain 50% inhibition of any of the 
17  off-target candidates when applied at 200 nmol/l (see 
Supplementary Materials). ALN-HTT01 was also tested for 
stability in cerebrospinal fluid (CSF) collected from individu-
als with normal HTT CAG repeat lengths and from both pre-
symptomatic and symptomatic HD mutant gene carriers and 
patients. Greater than 80% recovery of the full-length anti-
sense strand was obtained after 8 hours incubation in CSF at 
37 °C independent of the clinical stage of the disease of the 
CSF donor (data not shown).
The siRNA used for this study is a radiolabeled version 
of ALN-HTT01. It was synthesized and purified according to 
standard procedures, but with the following modifications for 
radiolabeling. Specifically, a deoxythymidine phosphorami-
dite building block 14C-labeled at C-4 was synthesized and 
coupled to a solid-support-bound, protected oligonucleotide 
precursor, followed by deprotection and anion-exchange 
HPLC purification of the radiolabeled antisense strand (AM 
Chemicals, LLC, Oceanside, CA). The radiolabeled antisense 
strand was then annealed to the unlabeled sense strand, 
and diluted in PBS. The HTT mRNA suppression activity of 
the radiolabeled siRNA was confirmed by an in vitro dose–
response assay in HeLa cells to be essentially identical to 
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that of ALN-HTT01. The final specific activity of this 14C-siHtt 
was 2.0 μCi/mg, and osmolarity and endotoxin levels were 
confirmed to be within acceptable levels.
siRNA delivery. Monkeys were infused with test articles (PBS, 
or 12 mg/ml siRNA in PBS) by transcutaneously refilling the 
abdominally implanted pump with the appropriate article on 
the planned days per the experimental design outlined in 
 Figure 1a. The refill procedures were performed in the animals 
under anesthesia using aseptic techniques. First, the reservoir 
refill port was located by palpating the skin over the pump. Then, 
a sterile 22-gauge noncoring needle was inserted through the 
skin and the silicone septum of the port until the needle con-
tacted the pump’s internal reservoir needle stop. The existing 
contents of the reservoir were aspirated and discarded, then 
the reservoir was rinsed twice with 5 ml of test article. Upon 
final aspiration of the rinse volume, the reservoir was filled with 
20 ml of test article and the refill needle was removed.
Tissue harvesting and processing. Animals were euthanized by 
transcardial perfusion of ice-cold saline under general anesthe-
sia per University of Kentucky standard operating  procedures. 
The unfixed brain was removed from the skull and cut into seven 
2-mm thick coronal sections, with one section at the infusion 
site, and three additional sections anterior, and three posterior 
to the infusion site. The tissue was frozen, stored at −70 °C, 
and sent on dry ice to a contract laboratory (QPS LLC, Newark, 
Delaware) for processing, including sectioning for quantitative 
autoradiography and subsequent tissue  punching. Briefly, the 
2-mm thick brain slabs were secured with carboxymethylcellu-
lose to a microtome plate, and sectioned just enough to produce 
a coronal section spanning the entire brain. Then, the next two 
 40-μm-thick sections were removed and used for autoradiogra-
phy. Punches were then harvested from the remaining tissue at 
prespecified locations by pressing a Harris tissue punch (Harris 
Uni-Core 1.25 mm, American MasterTech, Lodi, CA) into the 
tissue to collect a tissue “core.” The resulting tissue samples 
were placed in 1 ml of Trizol reagent (Life Technologies, Grand 
Island NY), and stored at −80 °C until later analyzed by RT-
qPCR for HTT and GAPDH mRNA levels.
Autoradiography. The tissue sections for quantitative auto-
radiography were covered with plastic wrap and exposed to 
phosphorimaging screens. Carbon 14 radiolabeled 
 glucose-spiked blood calibration standards were coexposed 
with all sections and the images were used for calibrating the 
image analysis software. The exposed screens were scanned 
using a Molecular Dynamics Typhoon 9410 Phosphor Imager 
(GE Healthcare Life Sciences, Pittsburgh, PA) and image 
calibration and concentration profile data were acquired as 
millicandellas per square millimeter. The calibrated standard 
curve enabled the conversion of the autoradiographic sig-
nal to units of microcuries per gram of tissue (μCi/g). The 
images were stacked and aligned in Amira software (version 
5.4.5, FEI Visualization Sciences Group, Burlington, MA) in a 
fashion resembling an MRI image stack. Using this stack, the 
approximate “volume of ≥45% suppression” was calculated 
for each monkey by identifying the area within each slice 
where the tissue concentration was greater than 0.65 mg of 
siRNA per gram of tissue. This tissue concentration has been 
previously determined7
 to correspond to 45% suppression 
of HTT mRNA, used as a target value for potential clinical 
effect. The labeled area in each slice was multiplied by 2 mm 
(the distance between successive slices) to convert area to 
 volume. The total volume of ≥45% suppression for each mon-
key is the sum of the individual slice volumes.
RNA isolation. Tissue punch samples were homogenized 
in a TissueLyser (Qiagen, Valencia, CA) then total RNA was 
isolated from each sample using the RNeasy Lipid Tissue Kit 
(Qiagen) according to the manufacturer’s protocol. The optional 
on-column DNase I digestion step of the manufacturer’s proto-
col was performed to remove any genomic DNA contamination. 
RNA was eluted twice in 40 μl of  nuclease-free water (final elu-
tion volume of 80 μl) to maximize the total RNA yield. Follow-
ing elution, a NanoDrop ND-1000 Spectrophotometer (Thermo 
Fisher Scientific, Wilmington, DE) was used to determine the 
RNA concentration and to measure the ratio of absorbance at 
wavelengths of 260 and 280 nm (A260/A280 ratio), a standard 
means of assessing RNA sample purity. The integrity and qual-
ity of the RNA was further characterized using an Agilent (Palo 
Alto, CA) 2100 Bioanalyzer. Analysis was performed using the 
Agilent RNA Pico 6000 kit. The RNA integrity number and asso-
ciated electropherogram for each sample was used to assess 
RNA integrity and quality. To be included in the final analysis, the 
RNA sample from a given tissue punch was required to have an 
RNA integrity number (indicator of lack of degradation) equal 
to 6.0 or greater, and an A260/A280 ratio (indication of purity) 
equal to 1.6 or greater. Out of 1,049 tissue punches, 5 were 
eliminated due to failure to meet the integrity criterion, and 21 
more were eliminated due to failure to meet the purity criterion.
Measurement of Huntingtin mRNA suppression. For cDNA 
synthesis, 200 ng of total RNA from a given tissue punch 
was used in a reverse transcription reaction (High Capac-
ity cDNA Reverse Transcription Kit, Applied Biosystems, 
 Foster City, CA) following the manufacturer’s protocol. For the 
measurement of HTT mRNA, a custom TaqMan assay spe-
cific for rhesus monkey HTT consisting of a forward primer 
(ggcagcttcggagtgaca), reverse primer (tgctgtgtatgatgtaacgtc 
agtt) and monkey HTT Taqman probe (cagcttgtccaggtttat) 
was used. An assay specific for rhesus monkey GAPDH 
(Assay ID Rh02621745_g1) was validated by and purchased 
from Applied Biosystems and served as the endogenous 
control in the experiments performed.
All cDNA samples were run in triplicate reactions for both 
HTT and GAPDH. Both “no reverse transcriptase” and “no 
cDNA template” controls were assayed in parallel to the mon-
key tissue samples to insure that there had been no DNA con-
tamination of either the cDNA synthesis or the amplification 
steps. To allow meaningful comparison of PCR results across 
sample plates and runs, a cDNA standard was included on all 
plates. This standard was prepared by pooling total RNA iso-
lated from three tissue punches harvested from the putamen 
of a surgically naive rhesus monkey, then converting that 
RNA to cDNA. Runs were analyzed setting the PCR cycle 
threshold values to a constant 0.55 for the target (HTT) and a 
constant 0.53 for GAPDH across all plates and runs.
For a given tissue punch to be included in the final data anal-
ysis, the PCR results for three replicate reactions for its RNA 
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sample were required to be internally consistent. Specifically, 
the HTT cycle thresholds for the replicates were required to 
have a standard deviation equal to or less than 0.1, and coeffi-
cient of variance (CV, standard deviation divided by the mean) 
equal to or less than 1 percent. Similarly, the standard devia-
tion and CV for GAPDH cycle thresholds were required to 
meet the same criteria. In addition, the cycle threshold for the 
GAPDH analysis was required to be no more than 10% higher 
than the average cycle threshold for GAPDH for all samples 
on the same analysis plate. Failure to meet this requirement 
would indicate that an excessively low amount of cDNA was 
present for the reaction to yield a reliable result; a similar cri-
terion did not apply to the cycle threshold for HTT, since a low 
amount of HTT could be a valid indicator of a high degree of 
HTT suppression. Failure to meet these acceptance criteria 
resulted in elimination of 53 (out of 1,049 total) tissue punches 
from the final analysis. Three more punches were eliminated 
because a determination of cycle thresholds for either HTT 
or GAPDH was not possible, and two more were eliminated 
because the resulting calculation of percent HTT suppression 
yielded implausible results (−720.4 and −2,197.9% suppres-
sion, respectively). The rate of tissue punch acceptance into 
the final analysis was comparable across the experimental 
groups: 197/211 (93.4%), 192/205 (93.7%), 194/212 (91.5%), 
196/215 (91.2%), and 186/206 (90.3%) for groups 1 through 5, 
respectively (chi-square test for differences = 2.39, P = 0.66).
To control for any difference in cDNA loading, all HTT 
expression data were normalized to the endogenous control 
specific for rhesus monkey GAPDH. To control for any reaction 
efficiency differences across assay plates or runs, the normal-
ized HTT expression was also adjusted by subtracting out the 
delta Ct obtained for the cDNA standard that was included in 
triplicate on every plate. Note that either order for these two 
steps is equivalent (algebraically identical). The steps of the 
ΔΔCt method of relative quantification14 are as follows.
ΔCt = (average HTT Ct – average GAPDH Ct)
 ΔΔCt = average ΔCt – (average ΔCt of the replicates of the 
cDNA standard)
 2 exp(− (ΔΔCt)) = normalized HTT amount standardized to 
the common plate-to-plate sample.
% Suppression = (1 − (2 exp(− (ΔΔCt)))) × 100
Finally, for ANOVAs and other significance tests of group 
 differences, the percent suppression of HTT was further nor-
malized by subtracting the average percent suppression for 
the corresponding PBS control group (group 1 in Figure 1), 
or the contemporaneous PBS group for the monkeys receiv-
ing siRNA for 1+6 days (in the meta-analysis of suppression 
onset). The computation of these averages and their sub-
traction from the percent suppression was done on a punch 
 location-by-punch location basis. However, for the mathemat-
ical modeling of onset time and the asymptote of percent sup-
pression attainable with this siRNA, the percent suppression 
was used directly, rather than the difference obtained after 
subtracting the average of the corresponding PBS group. The 
reason for this is described in the results section, and com-
mented upon in the discussion section.
Measurements of HTT suppression from tissue punches 
spanning 71 anatomical locations were available for analysis.
Modeling of the onset of HTT suppression. The time required 
for the siRNA to reach the brain from the SynchroMed II 
pump reservoir when delivered at a rate of 0.3 μl/minute fol-
lowing prior infusion of PBS into the brain is 23.29 hours, 
given a typical pump catheter and cranial catheter length of 
570 and 30 mm, respectively, resulting in 419.2 μl of “dead 
space” in the system. Therefore, the groups in the study that 
received siRNA for 2, 4, (or 7) days prior to termination were 
deemed to be time points 1, 3, (and 6) days, respectively, 
for analysis (or meta-analysis) of the onset of suppres-
sion upon siRNA delivery to the brain tissue. For purposes 
of mathematical modeling, the level of suppression at time 
point zero was considered to be zero percent, by definition. 
The overall approach used for the statistical analysis was 
first to conduct a mixed-model analysis of variance (ANOVA) 
of the PBS-normalized data using experiment group (time 
point) as a between-monkey factor, and punch location as a 
 within-monkey factor, because each monkey contributed sup-
pression data from multiple anatomical sites. The purpose of 
this analysis was to verify that some true differences in HTT 
suppression among groups and/or punch locations are pres-
ent in the data set, justifying proceeding to subanalyses for 
specific anatomical locations and groups. Next, data from 
each anatomical region of the brain (putamen, caudate, cere-
bral cortex, and white matter structures) were analyzed sepa-
rately by ANOVA. Finally, only for those regions of the brain in 
which statistically significant differences in HTT suppression 
among groups were found, one or two group planned t-tests 
were used to answer the following questions regarding the 
onset of HTT suppression: (i) does suppression differ from 
zero after 1 day of siRNA exposure? (ii) does suppression 
differ from zero after 3 days of siRNA exposure? (iii) is there 
greater suppression after 3 days than after 1 day of siRNA 
exposure?, and (iv) is there greater suppression after 6 days 
than after 3 days of exposure?
A further meta-analysis was performed (on the percent 
suppression data without subtracting the PBS average) to 
determine whether the onset of suppression in the treated 
monkeys as a function of time is linear or curvilinear, and 
if curvilinear, whether the best fitting curve is one that is 
 sigmoidal, or concave down. The equations chosen for this 
purpose were as follows:
Linear:  %Suppression = A + (B * day)
Sigmoidal:  %Suppression = A * e−e(B−C * day)
Concave down:  %Suppression = A * (1−e−B * day)
where day equals 1, 3, or 6. The analyses were performed 
using Minitab 16 (Microsoft, Redmond, WA) which solves for 
parameters A, B, and C in the respective equations by finding 
the set of values that minimizes the sum of squared devia-
tions of the observed data from the values predicted by the 
equation. The sum of squared deviations for the best linear, 
sigmoidal and concave down curve fit was used to compare 
the goodness of fit of the data to the equations.
Modeling of the duration of HTT suppression. The analysis of the 
time course of the duration of HTT suppression, and the nature 
of the rate of decline in suppression over time, involved com-
parison of HTT suppression across three groups of monkeys 
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all from the present study. The first group was the group (Group 
3, n = 3) that received siRNA for 4 days prior to termination 
(also used as time point 3 in the onset analysis, based on the 
time required for the siRNA to reach the brain from the pump, 
as described above). The second and third groups were those 
that received siRNA for 4 days, at which point their pumps were 
completely turned off, and who then were terminated 10 days 
(Group 4, n = 3) or 24 days (Group 5, n = 3) later. For math-
ematical modeling of the decline in suppression, these were 
considered to be time points 0, 10, and 24 days, respectively.
As with the analysis of onset, the overall approach was to 
first conduct a mixed-model ANOVA using experiment group 
(time point) as a between-monkey factor and punch location 
as a within-monkey factor to verify that some true differences 
in HTT suppression among groups and/or punch locations 
were present in the data set, justifying proceeding to sub-
analyses for specific anatomical locations and groups. Next, 
data from each anatomical region of the brain (putamen, cau-
date, cerebral cortex, and white matter structures) were ana-
lyzed separately by ANOVA. Finally, only for those regions of 
the brain in which statistically significant differences in HTT 
suppression among groups were found, one or two group 
planned t-tests were used to answer the following questions 
regarding the durability of HTT suppression: (i) does suppres-
sion differ from zero after three days of siRNA exposure (the 
starting point of the durability analysis)? (ii) does suppression 
still differ from zero 10 days after cessation of siRNA deliv-
ery? (iii) does suppression still differ from zero 24 days after 
cessation of siRNA delivery? (iv) is the decline in the amount 
of suppression with time linear or curvilinear, and if curvilin-
ear, is the best-fitting curve one that is concave down, or con-
cave up? The equations for these curve fits were as follows:
Linear: %Suppression = A + (B * day)
 Concave up  
(exponential decay):
%Suppression = A * e(−B * day)
Concave down: %Suppression = A − e(−B * day)
where day equals 0, 10, or 24. A and B are parameters found 
by Minitab by solving for the set of values that most minimizes 
the sum of squared deviations of the observed data from the 
values predicted by the equation. The sum of squared devia-
tions for the best linear, concave up (exponential decay) and 
concave down functions was used to compare the goodness 
of fit of the data to these functions.
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